Abhijeet Waghray1, Nisheet Waghray2, Adam T Perzynski1,3, Mark Votruba4,3, M Michael Wolfe5,6. 1. Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 44109, USA. 2. Division of Gastroenterology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA. 3. Center for Healthcare Research and Policy, Case Western Reserve University, Cleveland, OH, USA. 4. Department of Economics, Case Western Reserve University, Cleveland, OH, USA. 5. Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 44109, USA. michael.wolfe2@case.edu. 6. Division of Gastroenterology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA. michael.wolfe2@case.edu.
Abstract
BACKGROUND:Proton pump inhibitors (PPIs) are potent inhibitors of acid secretion and are the mainstay of therapy for gastroesophageal reflux disease (GERD). Initially designed to be taken 30 min before the first daily meal, these agents are commonly used suboptimally, which adversely affects symptom relief. No study to date has assessed whether correcting dosing regimens would improve symptom control. The objective of this study was to determine whether patients with persistent GERD symptoms on suboptimalomeprazole dosing experience symptomatic improvement when randomized to commonly recommended dosing regimen and to evaluate the economic impact of suboptimal PPI dosing in GERD patients. METHODS:Patients with persistent heartburn symptoms ≥ 3 times per week treated withomeprazole 20 mg daily were enrolled and randomized to commonly recommended dosing or continued suboptimal dosing of omeprazole. The primary outcomes were changes in symptom, frequency, and severity, as determined using the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) 4 weeks after the intervention was administered. In secondary analysis, an alternative measure of symptom load was used to infer potential costs. RESULTS:Sixty-four patients were enrolled. GSAS symptom, frequency, and severity scores were significantly better when dosing was optimized for overall and heartburn-specific symptoms (P < 0.01 for all parameters). Cost savings resulting from reduced medical care and workplace absenteeism were estimated to be $159.60 per treated patient, with cost savings potentially exceeding $4 billion annually in the USA. DISCUSSION: Low-cost efforts to promote commonly recommended PPI dosing can dramatically reduce GERD symptoms and related economic costs. ClinicalTrials.gov, number: NCT02623816.
RCT Entities:
BACKGROUND: Proton pump inhibitors (PPIs) are potent inhibitors of acid secretion and are the mainstay of therapy for gastroesophageal reflux disease (GERD). Initially designed to be taken 30 min before the first daily meal, these agents are commonly used suboptimally, which adversely affects symptom relief. No study to date has assessed whether correcting dosing regimens would improve symptom control. The objective of this study was to determine whether patients with persistent GERD symptoms on suboptimal omeprazole dosing experience symptomatic improvement when randomized to commonly recommended dosing regimen and to evaluate the economic impact of suboptimal PPI dosing in GERDpatients. METHODS:Patients with persistent heartburn symptoms ≥ 3 times per week treated with omeprazole 20 mg daily were enrolled and randomized to commonly recommended dosing or continued suboptimal dosing of omeprazole. The primary outcomes were changes in symptom, frequency, and severity, as determined using the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) 4 weeks after the intervention was administered. In secondary analysis, an alternative measure of symptom load was used to infer potential costs. RESULTS: Sixty-four patients were enrolled. GSAS symptom, frequency, and severity scores were significantly better when dosing was optimized for overall and heartburn-specific symptoms (P < 0.01 for all parameters). Cost savings resulting from reduced medical care and workplace absenteeism were estimated to be $159.60 per treated patient, with cost savings potentially exceeding $4 billion annually in the USA. DISCUSSION: Low-cost efforts to promote commonly recommended PPI dosing can dramatically reduce GERD symptoms and related economic costs. ClinicalTrials.gov, number: NCT02623816.
Authors: Benjamin Lazarus; Yuan Chen; Francis P Wilson; Yingying Sang; Alex R Chang; Josef Coresh; Morgan E Grams Journal: JAMA Intern Med Date: 2016-02 Impact factor: 21.873
Authors: David O Francis; Jennifer A Rymer; James C Slaughter; Yash Choksi; Pawina Jiramongkolchai; Evbu Ogbeide; Christopher Tran; Marion Goutte; C Gaelyn Garrett; David Hagaman; Michael F Vaezi Journal: Am J Gastroenterol Date: 2013-04-02 Impact factor: 10.864
Authors: David C Metz; John M Inadomi; Colin W Howden; Sander J Veldhuyzen van Zanten; Peter Bytzer Journal: Am J Gastroenterol Date: 2007-03 Impact factor: 10.864
Authors: Hashem B El-Serag; Nancy J Petersen; Junaia Carter; David Y Graham; Peter Richardson; Robert M Genta; Linda Rabeneck Journal: Gastroenterology Date: 2004-06 Impact factor: 22.682
Authors: M Guslandi; P A Testoni; S Passaretti; E Masci; E Ballarin; U Comin; R Marchi; G Ronchi; A Tittobello Journal: Hepatogastroenterology Date: 1983-06
Authors: S Vigneri; R Termini; G Leandro; S Badalamenti; M Pantalena; V Savarino; F Di Mario; G Battaglia; G S Mela; A Pilotto Journal: N Engl J Med Date: 1995-10-26 Impact factor: 91.245
Authors: Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler Journal: Am J Gastroenterol Date: 2022-01-01 Impact factor: 10.864
Authors: Fernando Sierra-Arango; D M Castaño; Jennifer D Forero; Erika D Pérez-Riveros; Gerardo Ardila Duarte; Maria L Botero; Andres Cárdenas; Jose De la Hoz-Valle Journal: Can J Gastroenterol Hepatol Date: 2019-12-12